Tamara Thelemann

Title: Tamara Thelemann: Innovator in Immunotherapy

Introduction

Tamara Thelemann is a prominent inventor based in Munich, Germany. She has made significant contributions to the field of immunotherapy, particularly in the development of oligonucleotides for cancer treatment. With a total of 2 patents, her work is paving the way for innovative therapeutic approaches.

Latest Patents

One of her latest patents is titled "Immunosuppression-reverting oligonucleotides inhibiting the expression of CD39." This invention refers to immunosuppression-reverting oligonucleotides comprising 12 to 18 nucleotides, wherein at least one of the nucleotides is modified. The oligonucleotide hybridizes with a nucleic acid sequence of an ectonucleotidase (NTPdase; CD73) of SEQ ID NO.1 (human), inhibiting at least 50% of the CD39 expression. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide. Another significant patent is "Antisense oligonucleotides for inhibition of PD-L1 expression and treating cancer." This invention relates to a novel approach for treating cancer, which is based on targeting PD-L1 mRNA. It is directed to oligonucleotides comprising 10 to 20 modified or unmodified nucleotides complementary to specifically selected regions of the PD-L1.

Career Highlights

Tamara Thelemann is currently associated with Secarna Pharmaceuticals GmbH & Co. KG, where she continues to advance her research in the field of immunotherapy. Her innovative work has garnered attention and respect within the scientific community.

Collaborations

Some of her notable coworkers include Frank Jaschinski and Richard Klar, who contribute to her research endeavors and collaborative projects.

Conclusion

Tamara Thelemann is a trailblazer in the field of immunotherapy, with her patents reflecting her commitment to advancing cancer treatment. Her work continues to inspire and pave the way for future innovations in the medical field.